Cargando…

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis

Brain metastases are the major cause of life-expectancy shortened for patients with lung cancer. The prognostic value of EGFR mutation subtypes and survival benefit of EGFR-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) patients with de novo brain metastasis is stil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Lei, Wang, Wen-xian, Wang, Dong, Lin, Li, Zhu, You-cai, Wang, Hong, Wang, Li-ping, Zhuang, Wu, Fang, Mei-yu, Wan, Bing, Feng, Hui-jing, Xu, Chun-wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847653/ https://www.ncbi.nlm.nih.gov/pubmed/33531991 http://dx.doi.org/10.7150/jca.51411

Ejemplares similares

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2019)

Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study
por: Lei, Lei, et al.
Publicado: (2020)

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2020)

The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer
por: Chang, Yu-Ping, et al.
Publicado: (2017)

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs
por: Xu, Chun-wei, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Sun, Lei, et al.
Publicado: (2023)

RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
por: Wang, Ping, et al.
Publicado: (2023)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer
por: Liu, Lei, et al.
Publicado: (2023)

The map of bone metastasis in nasopharyngeal carcinoma: A real‐world study
por: Luo, Dong‐Hua, et al.
Publicado: (2023)

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
por: Yang, Yaning, et al.
Publicado: (2023)

Real-world Evidence of the Herb-drug Interactions
por: Pan, Hsueh-Yi, et al.
Publicado: (2022)

A De Novo Transcriptome and Valid Reference Genes for Quantitative Real-Time PCR in Colaphellus bowringi
por: Tan, Qian-Qian, et al.
Publicado: (2015)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
por: Zhu, You-cai, et al.
Publicado: (2018)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival
por: Liu, Zongzhi, et al.
Publicado: (2023)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis
por: Yang, Beibei, et al.
Publicado: (2023)

Lymph node metastasis in Chinese patients with clinical T1 non‐small cell lung cancer: A multicenter real‐world observational study
por: Chen, Bing, et al.
Publicado: (2019)

Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study
por: Li, Xiao-Ping, et al.
Publicado: (2022)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

The use of paclitaxel coated balloon (PCB) in acute coronary syndrome of small vessel de novo lesions: an analysis of a prospective ‘real world’ registry
por: Mahmood Zuhdi, Ahmad Syadi, et al.
Publicado: (2016)

A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial
por: Zheng, Jiyang, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhang, Kun, et al.
Publicado: (2020)

Impact of Age of Onset on Survival after Hepatectomy for Patients with Colorectal Cancer Liver Metastasis: A Real-World Single-Center Experience
por: Wang, Hong-Wei, et al.
Publicado: (2022)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
por: Yang, Guangjian, et al.
Publicado: (2022)

A narrative review of hydrogen oncology: from real world survey to real world evidence
por: Chen, Ji-Bing, et al.
Publicado: (2020)

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
por: Liang, Hongge, et al.
Publicado: (2019)

Prognostic Score for De Novo Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit
por: Ji, Lei, et al.
Publicado: (2021)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
por: Li, Hong-Shuai, et al.
Publicado: (2022)

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
por: Zhu, You-cai, et al.
Publicado: (2017)

Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma
por: Luo, Hua-Chun, et al.
Publicado: (2023)

Improved Identification of Small Open Reading Frames Encoded Peptides by Top-Down Proteomic Approaches and De Novo Sequencing
por: Wang, Bing, et al.
Publicado: (2021)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
por: Zeng, Fujuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lfpmgkqu52f9vkdp6p8ln2pulk